THE NUCALA PATIENT

NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.

WHEN THIS IS YOUR COPD PATIENT, IT’S TIME TO THINK NUCALA:

At risk of exacerbations*† on triple inhaled therapy‡ with BEC ≥150 cells/μL

†Symptoms requiring intervention.1

*Moderate exacerbations defined as exacerbations (worsening of COPD symptoms) requiring treatment with systemic corticosteroids and/or antibiotics. Severe exacerbations defined as those requiring hospitalization (≥24 hours) or resulting in death.1

Are your COPD patients at risk for exacerbations and related hospital visits?§

COPD patient Nicholas floating in a pool in an inner tube

MEET NICHOLAS

  • Symptomatic despite being on SITT (ie, TRELEGY)
  • BEC: 220 cells/µL (a biomarker of type 2 inflammation2)
  • GOLD 3 (FEV1: 41%)
  • Chronic bronchitis
  • Current smoker
  • History: 2 moderate exacerbations requiring OCS bursts in last year
COPD patient Anna holding stuffed animals with her granddaughter

MEET ANNA

  • Symptomatic despite being on MITT
  • BEC: 385 cells/µL (a biomarker of type 2 inflammation2)
  • GOLD 4 (FEV1: 28%)
  • Emphysema without chronic bronchitis
  • Former smoker
  • History: 1 severe exacerbation requiring hospitalization in last year

§Annualized rate of exacerbations and those requiring hospitalization and/or ED visit were primary and descriptive secondary endpoints, respectively.3 See MATINEE and METREX results here.

If triple inhaled therapy‡ is not enough for your patients like Nicholas and Anna, consider adding NUCALA

SEE EFFICACY DATA

‡ICS + LABA + LAMA.

BEC=blood eosinophil count; ED=emergency department; FEV1=forced expiratory volume at 1 second; GOLD=Global Initiative for Chronic Obstructive Lung Disease; ICS=inhaled corticosteroid; LABA=long-acting beta2-agonist; LAMA=long-acting muscarinic antagonist; MITT=multiple-inhaler triple therapy; OCS=oral corticosteroid; SITT=single-inhaler triple therapy.

Woman shaking hands with man at outdoor farmers market

Start your patient on NUCALA

Begin with the enrollment form. See the resources that MyNUCALA offers to eligible patients, such as:

  • Savings & access options
  • 1-on-1 support team assistance
  • Text reminders & more
GO TO ACCESS & SUPPORT

Navigate a NUCALA prescription

Start with MyNUCALAkeyboard_arrow_right

INDICATIONS & IMPORTANT SAFETY INFO

INDICATIONS

IMPORTANT SAFETY INFORMATION

INDICATIONS

NUCALA is indicated for the: 

  • add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.
  • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids.
  • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Discontinue if a hypersensitivity reaction occurs.

 

Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease

NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.

 

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

 

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

 

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

 

ADVERSE REACTIONS

Most common adverse reactions (≥5%):

  • Severe asthma trials: headache, injection site reaction, back pain, fatigue
  • CRSwNP trial: oropharyngeal pain, arthralgia
  • COPD trials: back pain, diarrhea, cough
  • EGPA and HES trials (300 mg of NUCALA): most common adverse reactions were similar to severe asthma

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

 

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

 

Please see full Prescribing Information and Patient Information for NUCALA.

PMUS-MPLWCNT250056 June 2025

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References

  1. Data on file, GSK.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 report. https://goldcopd.org/2025-gold-report/. Accessed March 6, 2025.
  3. Sciurba FC, et al. Mepolizumab to prevent exacerbations in COPD with an eosinophilic phenotype. N Engl J Med. 2025;392:1710-1720.